X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Fresenius Kabi Onco. - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs FRESENIUS KABI ONCO. - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS FRESENIUS KABI ONCO. IPCA LABS/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 27.5 22.1 124.5% View Chart
P/BV x 2.1 3.1 67.8% View Chart
Dividend Yield % 0.2 0.0 -  

Financials

 IPCA LABS   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    IPCA LABS
Mar-17
FRESENIUS KABI ONCO.
Mar-13
IPCA LABS/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs643176 365.3%   
Low Rs50379 640.5%   
Sales per share (Unadj.) Rs254.437.7 675.1%  
Earnings per share (Unadj.) Rs16.15.1 315.5%  
Cash flow per share (Unadj.) Rs29.86.7 442.9%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs194.642.5 457.3%  
Shares outstanding (eoy) m126.20158.23 79.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.33.4 66.7%   
Avg P/E ratio x35.725.0 142.7%  
P/CF ratio (eoy) x19.218.9 101.7%  
Price / Book Value ratio x2.93.0 98.5%  
Dividend payout %6.20-   
Avg Mkt Cap Rs m72,30020,135 359.1%   
No. of employees `00013.31.2 1,154.8%   
Total wages/salary Rs m6,960703 989.7%   
Avg. sales/employee Rs Th2,413.55,176.2 46.6%   
Avg. wages/employee Rs Th523.2610.4 85.7%   
Avg. net profit/employee Rs Th152.4699.6 21.8%   
INCOME DATA
Net Sales Rs m32,1065,963 538.4%  
Other income Rs m22618 1,253.9%   
Total revenues Rs m32,3325,981 540.6%   
Gross profit Rs m4,4481,430 311.0%  
Depreciation Rs m1,730258 670.6%   
Interest Rs m241-26 -926.2%   
Profit before tax Rs m2,7031,216 222.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m675342 197.3%   
Profit after tax Rs m2,028806 251.6%  
Gross profit margin %13.924.0 57.8%  
Effective tax rate %25.028.1 88.8%   
Net profit margin %6.313.5 46.7%  
BALANCE SHEET DATA
Current assets Rs m17,3405,102 339.9%   
Current liabilities Rs m9,5592,385 400.7%   
Net working cap to sales %24.245.6 53.2%  
Current ratio x1.82.1 84.8%  
Inventory Days Days100150 66.9%  
Debtors Days Days57113 50.2%  
Net fixed assets Rs m20,7795,148 403.6%   
Share capital Rs m252158 159.5%   
"Free" reserves Rs m24,4996,556 373.7%   
Net worth Rs m24,5536,732 364.7%   
Long term debt Rs m3,517952 369.4%   
Total assets Rs m39,59510,388 381.2%  
Interest coverage x12.2-45.8 -26.7%   
Debt to equity ratio x0.10.1 101.3%  
Sales to assets ratio x0.80.6 141.3%   
Return on assets %5.77.5 76.3%  
Return on equity %8.312.0 69.0%  
Return on capital %10.514.6 71.8%  
Exports to sales %48.674.5 65.3%   
Imports to sales %14.224.8 57.5%   
Exports (fob) Rs m15,6174,441 351.7%   
Imports (cif) Rs m4,5711,477 309.4%   
Fx inflow Rs m15,6175,298 294.8%   
Fx outflow Rs m5,8281,772 328.8%   
Net fx Rs m9,7903,525 277.7%   
CASH FLOW
From Operations Rs m2,7641,274 217.0%  
From Investments Rs m-1,432-1,204 118.9%  
From Financial Activity Rs m-1,591-196 811.5%  
Net Cashflow Rs m-259-126 204.9%  

Share Holding

Indian Promoters % 45.9 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 11.4 0.3 3,800.0%  
FIIs % 25.3 9.6 263.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 9.1 191.2%  
Shareholders   36,892 42,599 86.6%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   BIOCON LTD  CADILA HEALTHCARE  SUVEN LIFE  DR. DATSONS LABS  WOCKHARDT LTD.  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Bank & Realty Stocks Rally(Closing)

Indian share markets surged further in the afternoon session and finished in the green for the second straight session on heavy buying in realty stocks, metal stocks and bank stocks.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Aug 23, 2017 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - AUROBINDO PHARMA COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS